Mitochondrial transplantation sensitizes chemotherapy to inhibit tumor development by enhancing anti-tumor immunity.

IF 5.6 2区医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Cancer Biology & Medicine Pub Date : 2025-06-19 DOI:10.20892/j.issn.2095-3941.2024.0596

Shumeng Lin, Liuliu Yuan, Xiao Chen, Shiyin Chen, Mengling Wei, Bingjie Hao, Tiansheng Zheng, Lihong Fan

{"title":"Mitochondrial transplantation sensitizes chemotherapy to inhibit tumor development by enhancing anti-tumor immunity.","authors":"Shumeng Lin, Liuliu Yuan, Xiao Chen, Shiyin Chen, Mengling Wei, Bingjie Hao, Tiansheng Zheng, Lihong Fan","doi":"10.20892/j.issn.2095-3941.2024.0596","DOIUrl":null,"url":null,"abstract":"Objective: Lung cancer is the leading cause of cancer-related deaths worldwide. Chemotherapy is associated with side effects, such as damage to myeloid cells and a reduction in the number of immune cells in patients. In addition, tumor cells hijack the mitochondria of immune cells through tunnel nanotubes, thereby weakening immune ability.Methods: In this study the effects of direct mitochondria transplantation on cancer cell proliferation and chemotherapeutic sensitivity were determined, as well as anti-tumor immunity in in vitro and in vivo lung cancer models.Results: A combination of mitochondrial transplantation and cisplatin chemotherapy was shown for the first time to significantly improve immune infiltration of advanced non-small cell lung cancer (NSCLC) and overcome the shortcomings of cisplatin chemotherapy, including damage to myeloid cells and a reduction in the number of immune cells.Conclusions: The findings of the current study provide valuable recommendations for enhancing immune infiltration and augmenting anti-tumor efficacy during chemotherapy in advanced NSCLC. In addition, the findings support \"mitochondrial transfer\" as a novel paradigm in tumor treatment.","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":" ","pages":""},"PeriodicalIF":5.6000,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12240198/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Biology & Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.20892/j.issn.2095-3941.2024.0596","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Lung cancer is the leading cause of cancer-related deaths worldwide. Chemotherapy is associated with side effects, such as damage to myeloid cells and a reduction in the number of immune cells in patients. In addition, tumor cells hijack the mitochondria of immune cells through tunnel nanotubes, thereby weakening immune ability.

Methods: In this study the effects of direct mitochondria transplantation on cancer cell proliferation and chemotherapeutic sensitivity were determined, as well as anti-tumor immunity in in vitro and in vivo lung cancer models.

Results: A combination of mitochondrial transplantation and cisplatin chemotherapy was shown for the first time to significantly improve immune infiltration of advanced non-small cell lung cancer (NSCLC) and overcome the shortcomings of cisplatin chemotherapy, including damage to myeloid cells and a reduction in the number of immune cells.

Conclusions: The findings of the current study provide valuable recommendations for enhancing immune infiltration and augmenting anti-tumor efficacy during chemotherapy in advanced NSCLC. In addition, the findings support "mitochondrial transfer" as a novel paradigm in tumor treatment.

查看原文本刊更多论文

线粒体移植使化疗增敏，通过增强抗肿瘤免疫抑制肿瘤发展。

目的：肺癌是全球癌症相关死亡的主要原因。化疗与副作用有关，如骨髓细胞受损和患者免疫细胞数量减少。此外，肿瘤细胞通过隧道纳米管劫持免疫细胞的线粒体，从而削弱免疫能力。方法：在体外和体内肺癌模型中，观察线粒体直接移植对癌细胞增殖、化疗敏感性以及抗肿瘤免疫的影响。结果：首次发现线粒体移植联合顺铂化疗可显著改善晚期非小细胞肺癌（NSCLC）的免疫浸润，克服顺铂化疗对骨髓细胞损伤、免疫细胞数量减少等缺点。结论：本研究结果为晚期非小细胞肺癌化疗期间增强免疫浸润和增强抗肿瘤疗效提供了有价值的建议。此外，研究结果支持“线粒体转移”作为肿瘤治疗的新范式。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Biology & Medicine Medicine-Oncology

CiteScore

9.80

自引率

3.60%

发文量

1143

审稿时长

12 weeks

期刊介绍： Cancer Biology & Medicine (ISSN 2095-3941) is a peer-reviewed open-access journal of Chinese Anti-cancer Association (CACA), which is the leading professional society of oncology in China. The journal quarterly provides innovative and significant information on biological basis of cancer, cancer microenvironment, translational cancer research, and all aspects of clinical cancer research. The journal also publishes significant perspectives on indigenous cancer types in China.